About Bio-Rad Laboratories, Inc.
https://www.bio-rad.comBio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments.
CEO
Norman D. Schwartz
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2002-03-08 | Forward | 2:1 |
| 1996-06-03 | Forward | 3:2 |
ETFs Holding This Stock
Summary
Showing Top 3 of 236
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 4 of 4
Price Target
Institutional Ownership
FIRST EAGLE INVESTMENT MANAGEMENT, LLC
Shares:2.52M
Value:$802.09M
VANGUARD GROUP INC
Shares:1.79M
Value:$570.79M
BLACKROCK, INC.
Shares:1.7M
Value:$539.7M
Summary
Showing Top 3 of 554
About Bio-Rad Laboratories, Inc.
https://www.bio-rad.comBio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $653M ▲ | $278.1M ▲ | $-341.9M ▼ | -52.36% ▼ | $-12.7 ▼ | $-384.6M ▼ |
| Q2-2025 | $651.6M ▲ | $268.2M ▼ | $317.8M ▲ | 48.77% ▲ | $11.67 ▲ | $477.2M ▲ |
| Q1-2025 | $585.4M ▼ | $282.3M ▼ | $64M ▲ | 10.93% ▲ | $2.29 ▲ | $133.5M ▲ |
| Q4-2024 | $667.48M ▲ | $283.58M ▼ | $-715.8M ▼ | -107.24% ▼ | $-25.57 ▼ | $-847.4M ▼ |
| Q3-2024 | $649.73M | $291.44M | $653.17M | 100.53% | $23.37 | $922.89M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $1.42B ▲ | $9.7B ▼ | $2.96B ▼ | $6.74B ▼ |
| Q2-2025 | $1.37B ▼ | $10.21B ▲ | $3.09B ▲ | $7.13B ▲ |
| Q1-2025 | $1.66B ▼ | $9.53B ▲ | $2.85B ▲ | $6.68B ▲ |
| Q4-2024 | $1.66B ▲ | $9.36B ▼ | $2.79B ▼ | $6.57B ▼ |
| Q3-2024 | $1.62B | $10.6B | $3.12B | $7.49B |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-341.9M ▼ | $120.9M ▲ | $-43M ▲ | $-52.5M ▲ | $26.5M ▲ | $89.2M ▲ |
| Q2-2025 | $-120.1M ▼ | $116.5M ▼ | $-115.4M ▼ | $-136.3M ▼ | $-151.4M ▼ | $70.8M ▼ |
| Q1-2025 | $64M ▲ | $129.9M ▲ | $2.9M ▲ | $-97.7M ▼ | $33.3M ▼ | $95.5M ▲ |
| Q4-2024 | $-715.8M ▼ | $124.15M ▼ | $-30.54M ▲ | $-26.25M ▲ | $77.61M ▲ | $81.25M ▼ |
| Q3-2024 | $653.2M | $163.61M | $-55.64M | $-95.99M | $4.47M | $99.97M |
Revenue by Products
| Product | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 Clinical Diagnostics | $390.00M ▲ | $360.00M ▼ | $390.00M ▲ | $390.00M ▲ |
 Life Science | $280.00M ▲ | $230.00M ▼ | $260.00M ▲ | $260.00M ▲ |
Revenue by Geography
| Region | Q4-2024 | Q1-2025 | Q3-2025 | Q2-2025 |
|---|---|---|---|---|
 Americas | $40.00M ▲ | $40.00M ▲ | $40.00M ▲ | $40.00M ▲ |
 Asia Pacific | $150.00M ▲ | $100.00M ▼ | $120.00M ▲ | $130.00M ▲ |
 Europe | $220.00M ▲ | $200.00M ▼ | $220.00M ▲ | $220.00M ▲ |
 UNITED STATES | $260.00M ▲ | $240.00M ▼ | $270.00M ▲ | $270.00M ▲ |
CEO
Norman D. Schwartz
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2002-03-08 | Forward | 2:1 |
| 1996-06-03 | Forward | 3:2 |
ETFs Holding This Stock
Summary
Showing Top 3 of 236
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 4 of 4
Price Target
Institutional Ownership
FIRST EAGLE INVESTMENT MANAGEMENT, LLC
Shares:2.52M
Value:$802.09M
VANGUARD GROUP INC
Shares:1.79M
Value:$570.79M
BLACKROCK, INC.
Shares:1.7M
Value:$539.7M
Summary
Showing Top 3 of 554